Literature DB >> 26895188

Recently identified drug resistance biomarkers in ovarian cancer.

Ben Davidson1,2.   

Abstract

Ovarian cancer, consisting mainly of ovarian carcinoma, is the most lethal gynecologic malignancy. Improvements in outcome for patients with advanced-stage disease are limited by intrinsic and acquired chemoresistance and by tumor heterogeneity at different anatomic sites and along disease progression. Molecules and cellular pathways mediating chemoresistance appear to be different for the different histological types of ovarian carcinoma, with most recent research focusing on serous and clear cell carcinoma. This review discusses recent data implicating various biomarkers in chemoresistance in this cancer, with focus on studies in which clinical specimens have been central.

Entities:  

Keywords:  DNA repair; Ovarian cancer; ascites; chemotherapy resistance; histology; microRNA; mitosis; progression

Mesh：

Substances：

Year:  2016        PMID： 26895188     DOI： 10.1586/14737159.2016.1156532

Source DB:  PubMed          Journal:  Expert Rev Mol Diagn        ISSN： 1473-7159            Impact factor:   5.225


  8 in total

1.  Expression and clinical role of the dipeptidyl peptidases DPP8 and DPP9 in ovarian carcinoma.

Authors:  Marta Brunetti; Arild Holth; Ioannis Panagopoulos; Anne Cathrine Staff; Francesca Micci; Ben Davidson
Journal:  Virchows Arch       Date:  2018-11-22       Impact factor: 4.064

2.  Transducin-Like Enhancer of Split 3 (TLE3) Expression Is Associated with Taxane Sensitivity in Nonserous Ovarian Carcinoma in a Three-Cohort Study.

Authors:  Brian Z Ring; Rajmohan Murali; Robert A Soslow; David D L Bowtell; Sian Fereday; Anna deFazio; Nadia Traficante; Catherine J Kennedy; Alison Brand; Raghwa Sharma; Paul Harnett; Goli Samimi
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2018-03-12       Impact factor: 4.254

3.  Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma.

Authors:  Hadil Onallah; Liora Jacobs Catane; Claes G Tropé; Thea E Hetland Falkenthal; Reuven Reich; Ben Davidson
Journal:  Virchows Arch       Date:  2018-07-21       Impact factor: 4.064

4.  Impact of the putative cancer stem cell markers and growth factor receptor expression on the sensitivity of ovarian cancer cells to treatment with various forms of small molecule tyrosine kinase inhibitors and cytotoxic drugs.

Authors:  Soozana Puvanenthiran; Sharadah Essapen; Alan M Seddon; Helmout Modjtahedi
Journal:  Int J Oncol       Date:  2016-09-05       Impact factor: 5.650

5.  MicroRNA-27b functions as a new inhibitor of ovarian cancer-mediated vasculogenic mimicry through suppression of VE-cadherin expression.

Authors:  Wenming Liu; Chunping Lv; Bin Zhang; Quansheng Zhou; Zhifei Cao
Journal:  RNA       Date:  2017-04-10       Impact factor: 4.942

Review 6.  Translational Physiology of Anti-Müllerian Hormone: Clinical Applications in Female Fertility Preservation and Cancer Treatment.

Authors:  Rachael Jean Rodgers; Jason Anthony Abbott; Kirsty A Walters; William Leigh Ledger
Journal:  Front Endocrinol (Lausanne)       Date:  2021-09-07       Impact factor: 5.555

7.  Identification of Specific Cell Subpopulations and Marker Genes in Ovarian Cancer Using Single-Cell RNA Sequencing.

Authors:  Yan Li; Juan Wang; Fang Wang; Chengzhen Gao; Yuanyuan Cao; Jianhua Wang
Journal:  Biomed Res Int       Date:  2021-10-07       Impact factor: 3.411

8.  Physical interaction of STAT1 isoforms with TGF-β receptors leads to functional crosstalk between two signaling pathways in epithelial ovarian cancer.

Authors:  Xiaoling Tian; Wencai Guan; Lingyun Zhang; Wenwen Sun; Daibing Zhou; Qunbo Lin; Weimin Ren; Lubna Nadeem; Guoxiong Xu
Journal:  J Exp Clin Cancer Res       Date:  2018-05-11
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.